Fibrin concentration of 10,000 simulations compared to experimental data of blood clotting over collagen/ TF under venous flow rate. by Jason Chen (15937)

Subjects:

GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

“…(C) COA6 cells were treated with GSK343 (0, 5 μM) for 72 hours. qPCR demonstrated a significant decrease in mRNA abundance of known stemness markers Oct4, Nanog, and Sox2 following GSK343 treatment compared to untreated cells. …”

Transient convection-diffusion of thrombin into and out of a fibrin domain exposed to venous flow. by Jason Chen (15937)

Subjects:

Serum samples and 50% NAI values. Serum samples taken from CEIRS study. by Harrison Powell (9040128)

Kaplan-Meier curves for the effect of VD₃ sufficiency vs. deficiency on survival of mice from BCR-ABL Arf-/- leukemia. by Kavya Annu (11587215)

K562 cells were treated with 40 nM of miR-214 mimics or a negative mimics control for 24 h, followed by treatment with 50 μM of hemin for 48 h. by Tipparat Penglong (164413)

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes by Yun Wu (150224)

Subjects:

ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

“…Chloramphenicol treated sample showed a decrease of half max intensity 30 mins after treatment.…”

Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation by Yaowaluk Tariwong (22630109)

Mitochondrial protein acetylation correlates with a decrease in sirtuin 3 levels. by Mercedes García-Roche (6459200)

Bacterial co-abundance networks decreases in complexity with lower host genetic variation. by Michael Ørsted (5926028)

C4BP is necessary and sufficient for serum-mediated decrease in neutrophil internalization of OpaD+ Gc. by Lacie M. Werner (14710419)

Quantifications of SEMG1-2 combined with measurements of CpG methylation levels in the Svs2 and Svs3ab promoters. by Ludwig Stenz (779897)

“…(D) Western blot quantifications revealing decreased SEMG2 in sperm of C57.D300.F1 (p<0.04) and C57.D300.F3 (p<0.004) compared with C57.CTL.F1. …”